Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy.

Heart (British Cardiac Society) - 1 Apr 2012

Ingles Jodie, McGaughran Julie, Scuffham Paul A, Atherton John, Semsarian Christopher

Abstract excerpt

BACKGROUND: Traditional management of families with hypertrophic cardiomyopathy (HCM) involves periodic lifetime clinical screening of family members, an approach that does not identify all gene carriers owing to incomplete penetrance and significant clinical heterogeneity. Limitations in availability and cost have meant genetic testing is not part of routine clinical management for many HCM families. OBJECTIVE:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Australia
Share to Cardiomyopathy, Hypertrophic, Familial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Genetic Carrier Screening

Share to Health Care Costs

Share to Markov Chains

Share to Quality-Adjusted Life Years

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 22128210
DOI: 10.1136/heartjnl-2011-300368

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy.PMID 22128210Read ↗

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness modelSemantic proximity Read ↗

A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathySemantic proximity Read ↗

A Systematic Review on the Cost-Effectiveness of Genetic and Electrocardiogram Testing for Long QT Syndrome in Infants and Young Adults.Semantic proximity Read ↗

Cascade health service use in family members following genetic testing in children: a scoping literature reviewSemantic proximity Read ↗

An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients.Semantic proximity Read ↗

Screening for Hereditary Hemochromatosis in Siblings and Children of Affected Patients: A Cost-Effectiveness AnalysisSemantic proximity Read ↗

A decision analysis model for diagnostic strategies using DNA testing for hereditary haemochromatosis in at risk populations.Semantic proximity Read ↗

Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.Semantic proximity Read ↗

Diagnostic strategies using DNA testing for hereditary haemochromatosis in at-risk populations: a systematic review and economic evaluation.Semantic proximity Read ↗

Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.Semantic proximity Read ↗

The uptake of family screening in hypertrophic cardiomyopathy and an online video intervention to facilitate family communication.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.